Activity-guided antithrombin III therapy in severe surgical sepsis: Efficacy and safety according to a retrospective data analysis

Shock

Volumn 30, Issue 6, 2008, Pages 634-641

  Moubarak, Patricia ^a   Zilker, Susanne ^a   Wolf, Hilde ^a   Hofner, Benjamin ^b   Kneib, Thomas ^b   Küchenhoff, Helmut ^b   Jauch, Karl Walter ^a   Hartl, Wolfgang H ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

Author keywords

Antithrombin III; Severe sepsis; Surgery

Indexed keywords

ANTITHROMBIN III; ANTITHROMBIN III CONCENTRATE;

ABDOMINAL ABSCESS; ADULT; AGED; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DYING; ERYTHROCYTE TRANSFUSION; FEMALE; FISTULA; HUMAN; INTENSIVE CARE UNIT; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIPLE ORGAN FAILURE; MULTIVARIATE ANALYSIS; PERITONITIS; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; PROTEIN BLOOD LEVEL; RETROSPECTIVE STUDY; SCORING SYSTEM; SEPSIS; SURGICAL PATIENT; SURVIVAL TIME;

AGED; ANTITHROMBIN III; FEMALE; HUMANS; INTENSIVE CARE UNITS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; RETROSPECTIVE STUDIES; SEPSIS; SERINE PROTEINASE INHIBITORS; TREATMENT OUTCOME;

EID: 58149260082     PISSN: 10732322     EISSN: None     Source Type: Journal    
DOI: 10.1097/SHK.0b013e31817d3e14     Document Type: Article

References (53)

1. Russell JA: Management of sepsis. N Engl J Med 355:1699-1713, 2006.
2. Leitner JM, Firbas C, Mayr FB, Reiter RA, Steinlechner B, Jilma B: Recombinant human antithrombin inhibits thrombin formation and interleukin 6 release in human endotoxemia. Clin Pharmacol Ther 79:23-34, 2006.
3. Hagiwara S, Iwasaka H, Matsumoto S, Noguchi T: High dose antithrombin III inhibits HMGB1 and improves endotoxin-induced acute lung injury in rats. Intensive Care Med 34:361-367, 2008.
4. Iba T, Kidokoro A: High-dose antithrombin therapy for sepsis: mechanisms of action. Shock 18:389-394, 2002.
5. Minneci PC, Deans KJ, Cui X, Banks SM, Natanson C, Eichacker PQ: Antithrombotic therapies for sepsis: a need for more studies. Crit Care Med 34:538-541, 2006.
6. Wiedemann CJ, Hoffmann JN, Juers M, Ostermann H, Kienast J, Briegel J, Strauss R, Keinecke HO, Warren BL, Opal SM, KyberSept Investigators: High-dose antithrombin III in the treatment of severe sepsis in patients with a high risk of death: efficacy and safety. Crit Care Med 34:285-292, 2006.
7. Warren BL, Eid A, Singer P, Pillay SS, Carl P, Novak I, Chalupa P, Atherstone A, Penzes I, Kubler A, et al. KyberSept Trial Study Group: caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial. JAMA 286:1869-1878, 2001.
8. Gonano C, Sitzwohl C, Meitner E, Weinstabl C, Kettner SC: Four-day antithrombin therapy does not seem to attenuate hypercoagulability in patients suffering from sepsis. Crit Care 10:R160, 2006.
9. Inthom D, Hoffmann JN, Hartl WH, Muhlbayer D, Jochum M: Antithrombin III supplementation in severe sepsis: beneficial effects on organ dysfunction. Shock 8:328-334, 1997.
10. Fourrier F, Chopin C, Huart JJ, Runge I, Caron C, Goudemand J: Doubleblind, placebo-controlled trial of antithrombin III concentrates in septic shock with disseminated intravascular coagulation. Chest 104:882-888, 1993.
11. Schneider CP, Wolf H, Küchenhoff H, Jauch KW, Haiti WH: Trends in der chirurgischen Intensivmedizin. 12 Jahre Erfahrung an einer einzelnen Institution. Chirurg 77:700-708, 2006.
12. Haiti WH, Wolf H, Schneider CP, Kiichenhoff H, Jauch KW: Secular trends in mortality associated with new therapeutic strategies in surgical critical illness. Am J Surg 194:535-541, 2007.
13. Rüttinger D, Wolf H, Kiichenhoff H, Jauch K-W, Haiti WH: Red cell transfusion: an essential factor for patient prognosis in surgical critical illness? Shock 28:165-171, 2007.
14. Müller M, Moubarak P. Wolf H, Küchenhoff H, Jauch K-W, Haiti WH: Independent determinants of early death in critically ill surgical patients. Shock 30:11-16, 2008.
15. Members of the American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference Committee: Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 20:864-874, 1992.
16. Blauhut B, Kramar H, Vinazzer H, Bergmann H: Substitution of antithrombin III in shock and DIC: a randomized study. Thromb Res 39:81-89, 1985.
17. Billing A, Fröhlich D, Mialkowskyj O. Stokstad P. Schildberg FW: Treatment of peritonitis with staged lavage: prognostic criteria and course of treatment. Langenbecks Arch Chir 377:305-313, 1992.
18. van Ruler O, Mahler CW, Boer KR, Reuland EA, Gooszen HG. Opmeer BC, de Graaf PW, Lamme B, Gerhards MF, Stellar EP, et al. Dutch Peritonitis Study Group: Comparison of on-demand vs planned relaparotomy strategy in patients with severe peritonitis: a randomized trial. JAMA 298:865-872. 2007.
19. Dellinger RP, Carlet JM, Masur H, Gerlach H, Calandra T, Cohen J, Gea- Banacloche J, Keh D, Marshall JC. Parker MM, et al.: Surviving Sepsis Campaign Management Guidelines Committee. Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock. Crit Care Med 32:858-873, 2004.
20. Wood SN: Stable and efficient multiple smoothing parameter estimation for generalized additive models. J Am Stat Assoc 99:673-686, 2004.
21. Wood SN: Modelling and smoothing parameter estimation with multiple quadratic penalties. J R Statist Soc B 62:413-428, 2000.
22. Wood SN: Generalized Additive Models. Boca Raton. FL: Chapman & Hall. 2006.
23. Greene W: Functional form and heterogeneity in models for count data. Fund Trends Econom 1:113-218, 2007.
24. Sylvestre MP, Huszti E, Hanley JA: Do OSCAR winners live longer than less successful peers? A reanalysis of the evidence. Ann Intern Med 145:361-363. 2006.
25. Kneib T, Fahrmeir L: A mixed model approach for geoadditive hazard regression. Scand J Stat 34:207-228, 2007.
26. Leisch F: FlexMix: a general framework for finite mixture models and latent class regression. J Stat Softw 11:1-18, 2004. Available at: http://www.jstatsoft.org/v11/i08/paper. Accessed December 12, 2007.
27. http://www.stat.uni-muenchen.de/~bayesx/bayesxdownload.html (last access 03/08).
28. Brezger A, Kneib T, Lang S, Bayes X: Analysing Bayesian structured additive regression models. J Stat Softw 14:1-22, 2005. Available at: http://www.jstatsoft.org/vl4/i11/paper. Accessed December 14, 2007.
29. Sakr Y, Reinhart K, Vincent JL, Sprung CL, Moreno R, Ranieri VM. De Backer D, Payen D: Does dopamine administration in shock influence outcome? Results of the Sepsis Occurrence in Acutely III Patients (SOAP) Study. Crit Care Med 34:589-597, 2006.
30. Engel C, Brunkhorst FM, Bone HG, Brunkhorst R, Gerlach H, Grand S. Gruendling M, Huhle G, Jaschinski U, John S, et al.: Epidemiology of sepsis in Germany: results from a national prospective multicenter study. Intensive Care Med 33:606-618, 2007.
31. Bernard GR, Vincent JL, Laterre PF. LaRosa SP, Dhainaut JF, Lopez- Rodriguez A, Steingrub JS, Garber GE, Helterbrand JD, Ely EW, et al.: Recombinant human protein C Worldwide Evaluation in Severe Sepsis (PROWESS) study group. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 344:699-709, 2001.
32. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR: Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 29:1303-1310, 2001.
33. Mesters RM, Mannucci PM, Coppola R, Keller T. Ostermann H, Kienast J: Factor VIIa and antithrombin III activity during severe sepsis and septic shock in neutropenic patients. Blood 88:881-886, 1996.
34. Fourrier F, Chopin C, Goudemand J, Hendrycx S, Caron C, Rime A, Marey A, Lestavel P: Septic shock, multiple organ failure, and disseminated intravascular coagulation. Compared patterns of antithrombin III, protein C. and protein S deficiencies. Chest 101:816-823, 1992.
35. Sakr Y, Reinhart K, Hagel S, Kientopf M, Brunkhorst F: Antithrombin levels, morbidity, and mortality in a surgical intensive care unit. Aneslh Analg 105:715-723, 2007.
36. Pettila V, Pentti J, Pettila M, Takkunen O, Jousela I: Predictive value of antithrombin III and serum C-reactive protein concentration in critically ill patients with suspected sepsis. Crit Care Med 30:271-275, 2002.
37. Minnema MC, Chang AC, Jansen PM, Lubbers YT, Pratt BM, Whittaker BG, Taylor FB, Hack CE, Friedman B: Recombinant human antithrombin III improves survival and attenuates inflammatory responses in baboons lethally challenged with Escherichia coli. Blood 95:1117-1123, 2000.
38. Taylor FB Jr, Emerson TE Jr. Jordan R, Chang AK, Blick KE: Antithrombin-III prevents the lethal effects of Escherichia coli infusion in baboons. Circ Shock 26:227-235, 1988.
39. Pulletz S, Lehmann C, Volk T, Schmutzler M, Ziemer S, Kox WJ, Scherer RU: Influence of heparin and hirudin on endothelial binding of antithrombin in experimental thrombinemia. Crit Care Med 28:2881-2886, 2000.
40. Opal SM, Kessler CM, Roemisch J, Knaub S: Antithrombin, heparin, and heparan sulfate. Crit Care Med 30(5 Suppl):S325-S331, 2002.
41. Oelschläger C, Römisch J, Staubitz A, Stauss H, Leithäuser B, Tillmanns H, Holschermann H: Antithrombin III inhibits nuclear factor kappaB activation in human monocytes and vascular endothelial cells. Blood 99:4015-4020, 2002.
42. Hoffmann JN, Wiedermann CJ, Juers M, Ostermann H, Kienast J, Briegel J, Strauss R, Warren BL, Opal SM, KyberSept investigators: Benefit/risk profile of high-dose antithrombin in patients with severe sepsis treated with and without concomitant heparin. Thromb Haemost 95:850-856, 2006.
43. Kienast J, Juers M, Wiedermann CJ, Hoffmann JN, Ostermann H, Strauss R, Keinecke HO, Warren BL, Opal SM, KyberSept investigators: Treatment effects of high-dose antithrombin without concomitant heparin in patients with severe sepsis with or without disseminated intravascular coagulation. J Thromb Haemost 4:90-97, 2006.
44. Afshari A, Wetterslev J, Brok J, Møller A: Antithrombin III in critically ill patients: systematic review with meta-analysis and trial sequential analysis. BMJ 334:1248-1251, 2007.
45. Wiedermann CJ, Kaneider NC: A systematic review of antithrombin concentrate use in patients with disseminated intravascular coagulation of severe sepsis. Blood Coagul Fibrinolysis 17:521-526, 2006.
46. Adhikari NK, Burns KE, Friedrich JO, Granton JT, Cook DJ, Meade MO: Effect of nitric oxide on oxygenation and mortality in acute lung injury: systematic review and meta-analysis. BMJ 334:779-787, 2007.
47. Sprung CL, Annane D, Keh D, Moreno R, Singer M, Freivogel K, Weiss YG, Benbenishty J, Kalenka A, Forst H, et al.: CORTICUS Study Group: Hydrocortisone therapy for patients with septic shock. N Engl J Med 358:111-124, 2008.
48. Freeman BD, Zehnbauer BA, Buchman TG: A meta-analysis of controlled trials of anticoagulant therapies in patients with sepsis. Shock 20:5-9, 2003.
49. Silliman CC, Moore EE, Johnson JL, Gonzalez RJ, Biffl WL: Transfusion of the injured patient: proceed with caution. Shock 21:291-299, 2004.
50. Hensler T, Heinemann B, Sauerland S, Lefering R, Bouillon B, Andermahr J, Neugebauer EA: Immunologic alterations associated with high blood transfusion volume after multiple injury: effects on plasmatic cytokine and cytokine receptor concentrations. Shock 20:497-502, 2003.
51. Zallen G, Moore EE, Ciesla DJ, Brown M, Biffl WL, Silliman CC: Stored red blood cells selectively activate human neutrophils to release IL-8 and secretory PLA2. Shock 13:29-33, 2000.
52. Aiboshi J, Moore EE, Ciesla DJ, Silliman CC: Blood transfusion and the twoinsult model of post injury multiple organ failure. Shock 15:302-306, 2001.
53. Prins HA, Houdijk AP, Nijveldt RJ, Teerlink T, Huygens P, Thijs LG, van Leeuwen PA: Arginase release from red blood cells: possible link in transfusion induced immune suppression? Shock 16:113-115, 2001.